A placebo-controlled randomised trial of intravenous lidocaine in accelerating gastrointestinal recovery after colorectal surgery

ACCORD0 个研究点目标入组 562 人开始时间: 2018年6月13日最近更新: 2023年8月2日

试验速览

2022 Protocol article in https://pubmed.ncbi.nlm.nih.gov/35090535/ (added 31/01/2022)

•Scheduled for elective colorectal resection for colorectal cancer or diverticular disease at participating UK colorectal surgery units. Right hemicolectomy, extended right hemicolectomy, left colectomy, sigmoid colectomy, subtotal colectomy with ileosigmoid or ileorectal anastomosis and high anterior resection are eligible.

•1. Planned epidural anaesthesia
•2. Planned regional or local infiltration of lidocaine at the same time as lidocaine infusion
•3. Pregnancy
•4. Breastfeeding
•5. Patients lacking capacity to give informed consent
•6. Known or suspected allergy to lidocaine or amide-type local anaesthetics
•7. Current complete heart block
•8. Current severe liver dysfunction (Child’s A or greater)
•9. Current renal failure (eGFR <30)
•10. Participation in the active intervention phase of another therapeutic clinical trial (or other interventional trial) unless a co-enrolment agreement is in place
•11. Patients having surgery for indications other than colorectal cancer/diverticular disease
•12. Rectal cancer below the peritoneal reflection in which total mesorectal excision is anticipated
•13. Rectal cancer patients who have received any neoadjuvant radiotherapy
•14. Preoperative surgical plan to form any new stoma during the primary procedure

发起方

ACCORD